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Abstract
The Pharmacovigilance Risk Assessment Committee (PRAC)
of the European Medicines Agency (EMA) earlier this year
recommended to suspend some marketing authorisations for
Gadolinium Containing Contrast Agents (GCCAs) based on
linear chelators due to the potential risk of gadolinium reten-
tion in the human body. These recommendations have recent-
ly been re-evaluated by EMA’s Committee for Medicinal
Products for Human Use (CHMP), and confirmed the final
opinion of the European Medicines Agency. This editorial
provides an overview of the available GCCAs and summa-
rises the recent evidence of gadolinium retention. Moreover, a
critical appraisal of the strengths and limitations of the scien-
tific evidence currently available on gadolinium retention is
given.
Key points
• EMA recommended suspension of some EU marketing
authorisations of four linear GCCAs.
• Brain MRI findings indicating gadolinium retention have
been confirmed by mass spectrometry.
• Current scientific evidence for gadolinium retention has sev-
eral methodological limitations.
• No clear clinical evidence exists indicating that gadolinium
retention causes neurotoxicity.
• Long-term safety of GCCAs, however, remains unclear.
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Abbreviations
CHMP Committee for Medicinal Products
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Gd Gadolinium
NSF Nephrogenic systemic fibrosis
PRAC Pharmacovigilance Risk Assessment
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Introduction
The Pharmacovigilance RiskAssessment Committee (PRAC) of
the EuropeanMedicines Agency (EMA) earlier this year recom-
mended suspending some marketing authorisations for
gadolinium-containing contrast agents (GCCAs) based on linear
chelators due to the potential risk of gadolinium retention in the
human body [1]. The recommendations made by the PRAC
were based on the evaluation of recent research findings indicat-
ing gadolinium retention in the brain, which can be measured as
increased signal intensities on T1-weighted sequences of
unenhanced MRI scans. The PRAC has re-evaluated its recom-
mendations based on questions by the marketing authorisation
holders, which has subsequently been confirmed by the
Committee for Medicinal Products for Human Use (CHMP).
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The CHMP is a regulatory organ within the EMAwith a central
role in the authorisation of medicines inside the European Union
(EU). On 21 July 2017, the EMA published its final opinion to
suspend and/or restrict some of the marketing authorisations of
four GCCAs based on linear chelators from the Europeanmarket
[2]. These four agents based on linear chelators are gadobenate
dimeglumine (MultiHance), gadodiamide (Omniscan),
gadopentetate dimeglumine (Magnevist) and gadoversetamide
(OptiMark). This is not the first time that linear gadolinium
agents are under investigation by the EMA. In 2007, exposure
to high doses of gadolinium were for the first time linked to the
development of nephrogenic systemic fibrosis (NSF) in patients
with severe renal insufficiency. In this period, the EMA gave a
serious warning (e.g. ‘Black Box’ warning) regarding the rela-
tionship between NSF and linear chelators; however, the scien-
tific evidence at that time was considered insufficient to proceed
with a ban from the European market. However, how strong is
the scientific evidence for the current recommendations andwhat
are the implications for radiology practice in the EU?
Physical chemistry of gadolinium-containing
contrast agents (GCCAs)
GCCAs can be classified into four different groups based on the
type of ligand (linear or macrocyclic) and charge (ionic or non-
ionic; Table 1). Gadolinium is a heavy metal from the lantha-
nide group with strong paramagnetic properties (shortening of
the proton T1 relaxation time), which is chelated by binding to a
strong ligand. In the linear chelates the gadolinium ion is bound
to an open-chain ligand, while in the macrocyclic chelates the
gadolinium ion is bound inside a cubic chemical structure.
These differences in the chemical structure of the ligands ex-
plain the difference in thermodynamic and kinetic stability,
whereby the non-ionic linear chelates are the least stable and
the ionic macrocyclic chelates are the most stable [3]. The free
gadolinium ion is mostly hydrated in biological systems, and
this Gd(H2O)8
3+ ion is toxic because of its chemical similarities
to Ca2+, which is an important factor for proper functioning of
many processes in the human body such as contraction of the
heart muscle and smooth muscle cells, and nerve transmission.
Gd3+ can compete with Ca2+ due to its similarity in ion radius,
and could thereby disturb physiological processes. In unstable
chelates, the gadolinium ion could, partly depending on the
local environment (acidic pH), become detached from the li-
gand by transmetallation (exchange with other ions present in
the local environment, such as Fe3+, Cu2+, or Zn2+ ions) and the
Gd3+ ion could then precipitate locally as a salt (gadolinium
hydroxide, gadolinium carbonate or gadolinium phosphate) or
bind to other macromolecules, such as proteins, peptides or
metalloenzymes [4].
Evidence for gadolinium retention
In 2014, Kanda et al. described a positive correlation between
previous exposure to GCCAs based on linear chelators and
increased signal intensity in basal ganglia on subsequent
unenhanced T1-weighted MRI sequences in 35 patients [5].
This increase in signal intensity was not found in the control
group, which consisted of patients who underwent multiple
MRI scans without the addition of a contrast agent. These
findings were soon replicated by multiple independent re-
search groups in different countries. To date, a total of 19
studies have been performed that investigated whether repeat-
ed exposure to GCCAs causes increased signal intensity in the
brain. Thus far, 15 out of 19 studies found a positive correla-
tion between the number of administrations of a linear chelate
and the measured signal intensity in the basal ganglia. At this
moment, the association has not been demonstrated for the
macrocyclic chelates [6, 7]. The four contrast agents that the
EMA has recommended suspending and/or restricting
Table 1 Current arsenal of linear and macrocyclic gadolinium-based contrast agents (GBCAs). Classification of available GBCAs into four different
groups based on the type of ligand (linear or macrocyclic) and charge (ionic or non-ionic), with corresponding brand name and manufacturer
Linear Macrocyclic
Ionic Ionic
Magnevist (gadopentetate dimeglumine – Bayer)
Magnevision (gadopentetate dimeglumine – B.E. Imaging)
Dotarem (gadoterate meglumine – Guerbet)
Clariscan (gadoterate meglumine – GE Healthcare)
Dotagraf (gadoterate meglumine – Bayer)
Dotagita (gadoterate meglumine – Agfa)
Cyclolux (gadoterate meglumine – Sanochemia)
MultiHance (gadobenate dimeglumine – Bracco)
Primovist (gadoxetate disodium – Bayer)
Non-ionic Non-ionic
Omniscan (gadodiamide – GE Healthcare) ProHance (gadoteridol – Bracco)
OptiMARK (gadoversetamide – Guerbet) Gadovist (gadobutrol – Bayer)
1580 Eur Radiol (2018) 28:1579–1584
marketing authorisations are all based on linear chelators (see
Table 2). Furthermore, small post-mortem studies showed the
presence ofminiscule amounts of gadolinium in brain tissue in
patients who received GCCAs in the past [8–10]. The recent
post-mortem study by Murata et al. found that gadolinium
deposition in normal brain and bone tissue occurs with both
agents based on macrocyclic (only nonionic, i.e. gadobutrol
and gadoteridol) and linear chelators in patients with normal
renal function [10]. Gadolinium retention in bone and skin had
already been described by histology studies [11, 12], and very
recent data based on autopsy studies suggest that gadolinium
can accumulate in other organs as well, such as the liver and
kidney [13, 14].
Methodological limitations of current studies
The studies performed thus far have several important limita-
tions that need to be considered when interpreting these data.
All studies have an observational retrospective design, which
makes these studies vulnerable to different forms of bias and
confounding. The retrospective data collection introduces un-
certainty about the number of administered doses and included
patients could have received different types of contrast agents
rather than solely linear or macrocyclic, which could lead to
misclassification bias. Furthermore, only few studies have suf-
ficiently corrected for potential confounders that could distort
the association between gadolinium exposure and an increased
signal intensity in the brain. Examples of such potential con-
founders are age, gender and follow-up time. Control groups
were also not always included in the analyses and if present
were often limited to small sample sizes and comprised differ-
ent patient populations compared to the exposed group.
Besides the above-mentioned methodological drawbacks,
there are also significant limitations to the use of increased
signal intensity as a primary outcome measure. The increased
signal intensity in the brain on MRI scans is not always reli-
able and comparable due to different field strengths (1.5 Tesla
and 3.0 Tesla), and the use of different T1-weighted sequences
or sequence parameters. Moreover, the proton T1 relaxivity
also depends on themolecular weight of the molecule towhich
the Gd-ions or Gd-contrast media molecules are attached (ei-
ther soluble macromolecules or insoluble cell components),
the water residence time of the coordinated water molecules,
and, for some GCCAs, the presence of albumin [15, 16]. It is
therefore unclear to what extent the increased signal intensity
in the brain truly reflects higher gadolinium concentrations
[17]. Each of the GCCAs possibly has a different level of
administered doses before signal changes can be observed on
MR images. It could be that for agents based on macrocyclic
chelators this level involves such a substantially high number
of administrations, which hardly occurs in individual patients
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Thus far, five post-mortem studies, all using inductively
coupled plasma mass spectroscopy, have measured levels of
elemental Gd in different brain areas with possibly intact
blood-brain barriers [8, 10, 17–19]. Overall, data are limited
to 31 patients exposed to either linear or macrocyclic-based
GCCAs compared to 28 controls. Only one study (N=13) has
assessed the possible distribution of Gd compounds in brain
tissues, and the possible presence of histological changes [18].
To summarise, these studies found that Gd deposition has been
observed in all 31 patients exposed to either linear or macro-
cyclic GCCAs, even after one single exposure, compared to
controls. Second, calculation of normalised Gd deposition ra-
tios (Gd deposited in 1 g of tissue per millimole of GCCA
administered) did not show significant differences between
linear and macrocyclic GCCAs. In contrast to the imaging-
based studies, the post-mortem study of Murata et al. suggests
that gadolinium retention is not solely limited to agents based
on linear chelators [8]. This suggests that extension of the
suspension of marketing authorisations to certain GCCAs
based on macrocyclic chelators cannot be completely ex-
cluded if more evidence becomes available. However, the
current number of patients studied in tissue analysis is too
small to draw any conclusions on differences among the
various GCCAs tested, and does not allow for differentia-
tion between the various forms of gadolinium (e.g. chelat-
ed Gd, Gd-associated macromolecules) as different
GCCAs with various cumulative doses and with heteroge-
neous sampling times have been studied.
The association between gadolinium accumulation and the
occurrence of physical symptoms or neurotoxic damage has
not been demonstrated yet. Thus far, two studies aimed to
assess the possible influence of gadolinium accumulation
and clinical symptoms [20, 21]. The study by Welk et al. in-
volving 99,739 patients with one or more Gd-enhanced MRI
and 146,818 control patients with only non-enhanced MRIs
did not find a significant association with parkinsonism [20].
A very recent retrospective cohort study involving nearly 20
years of longitudinal data in 23 multiple sclerosis patients and
23 healthy age- and sex-matched controls found a possible
association between Gd exposure and cognitive impairment
(verbal fluency) [21]. However, it should be noted that these
findings need to be interpreted with caution since retrospec-
tive studies are highly susceptible to ‘confounding by indica-
tion’. Patients requiring contrast administration in general tend
to be more ill than patients in whom contrast administration is
not needed, which biases the assessment of the effect of con-
trast media and clinical outcome. To test the association be-
tween Gd and clinical symptoms, one would ideally do a
prospective study with clinical symptoms as the study out-
come, whereby the patients are randomised for receiving con-
trast agents or not. However, a prospective study on rare clin-
ical outcomes is impracticable since very large sample sizes
are needed and are, furthermore, unethical. Previous animal
studies evaluating side effects of lanthanum carbonate, which
is a rare metal of the same lanthanide family as gadolinium,
have related this agent to reduced learning behaviour in rats at
lower concentrations than now found in humans for gadolin-
ium [22]. However, no direct neurotoxicity endpoints were
evaluated [23], and adverse effects on learning behaviour in
both humans and animals have not yet been described for
gadolinium. Nevertheless, caution is needed regarding patient
safety and unknown long-term effects. In this view, the advice
of the PRAC is understandable and probably a safe decision
considering the availability of several different classes of
GCCAs (Table 1). Additionally, as radiologists it is advisable
to keep in mind that for every diagnostic examination, espe-
cially when using contrast agents or radiation, a clear clinical
indication should be present, and to keep the contrast agent
dose as low as reasonably possible.
Implications
Following the PRAC’s March 2017 recommendation,
some of the marketing authorisation holders concerned
by this referral procedure have requested a re-examination.
Upon receipt of the grounds for their requests, the PRAC
has completed a re-examination, which was published on
7 July 2017. An additional assessment was performed by
the CHMP, which was unfavourable for the four linear
contrast agents regarding quality, safety and efficacy
requirements and risk-benefit analysis. The GCCAs that
fulfil an important diagnostic need in patients with few
alternatives such as the hepatobiliary specific linear agent
gadoxetic acid and a formulation of gadopentetic acid used
for MR arthrography, were excluded from the PRAC in-
vestigation and will thus maintain their marketing authori-
sation. In line with contrast agents fulfilling specific diag-
nostic needs, the use of gadobenic acid has been restricted
to liver MRI scans. The reactions to the statement in the
field have been diverse. For example, the Committee of
Contrast Media and Drugs of the American College of
Radiology previously noted finding the statement of the
PRAC premature and are not in favour of the suspension
of marketing authorisations of these agents for the US
market based on the current available data [24]. In
May 2017 the US Food and Drug Administration (FDA)
announced a safety update regarding the evaluation of the
risk of Gd accumulation associated with repeated adminis-
tration of GCCAs. The FDA concluded that although
GCCAs may be associated with some Gd retention in
the brain and other organs, no adverse health effects from
Gd retention have been identified. Previous recommenda-
tions of the FDA regarding the use of GCCAs remain
thus unchanged [25].
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International research cooperation
Since gadolinium retention in the body (in the brain but also in
bone, skin and liver) is a rare phenomenon, multiple centres in
Europe are collaborating to achieve international cooperation
on this topic. The European Gadolinium Retention Evaluation
Consortium (E-GREC), founded in 2016, is a collaboration of
academic clinical researchers and basic researchers from the
contrast agent manufacturers [26]. Additionally, the consor-
tium has close connections to researchers in the USA. E-
GREC will initially focus on acquiring resources to fund fu-
ture scientific projects and will focus on guidelines to improve
the quality of the preclinical and clinical research on gadolin-
ium retention.
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